Our meta-analysis confirmed that the slow acetylators carrying the allelic variants NAT2*5, 6, 7 were at a significantly higher risk of dose-dependent adverse events, such as nausea, vomiting, dizziness, but slow acetylation was not associated with hypersensitivity-related adverse events, such as skin rash or granulocytopenia (Supplementary Appendix 6 in Supplementary Table 6). The gene discussed is NAT2; the disease is exanthem.